BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37730020)

  • 1. Trends in price for topical corticosteroids from 2017 to 2021 and the opportunity for cost savings identifiable at the point of care: A retrospective cross-sectional study.
    Kwa M; Guttentag A; Chase L; van Meijgaard J; Lim HW
    J Am Acad Dermatol; 2024 Jan; 90(1):74-81. PubMed ID: 37730020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commentary on: "Trends in price for topical corticosteroids from 2017 to 2021 and the opportunity for cost savings identifiable at the point of care: A retrospective cross-sectional study".
    Kwa MC; Lim HW
    J Am Acad Dermatol; 2024 Jul; 91(1):192-193. PubMed ID: 38367673
    [No Abstract]   [Full Text] [Related]  

  • 3. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating Savings Opportunities From Therapeutic Substitutions of High-Cost Generic Medications.
    Socal MP; Cordeiro T; Anderson GF; Bai G
    JAMA Netw Open; 2022 Nov; 5(11):e2239868. PubMed ID: 36322082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends and determinants of retail prescription drug costs.
    Teasdale B; Nguyen A; van Meijgaard J; Schulman KA
    Health Serv Res; 2022 Jun; 57(3):548-556. PubMed ID: 35211965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of common oral and topical dermatologic medication price variation by source.
    Boyko A; Smith GP
    Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
    Rosenberg ME; Rosenberg SP
    JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased topical generic prices by manufacturers.
    Bhatt MD; Bhatt BD; Dorrian JT; McLellan BN
    J Am Acad Dermatol; 2019 May; 80(5):1353-1357. PubMed ID: 29544742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation.
    Green C; Colquitt JL; Kirby J; Davidson P; Payne E
    Health Technol Assess; 2004 Nov; 8(47):iii,iv, 1-120. PubMed ID: 15527669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Discounted and Undiscounted Cash Prices for Cardiovascular Medications by Type of US Community Pharmacy.
    Hong M; Shcherbakova N
    J Gen Intern Med; 2021 Jan; 36(1):114-120. PubMed ID: 32885368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
    Carroll NV
    J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription drug costs and the generic dispensing ratio.
    Liberman JN; Roebuck MC
    J Manag Care Pharm; 2010 Sep; 16(7):502-6. PubMed ID: 20726679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
    Johnsrud M; Lawson KA; Shepherd MD
    J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
    Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
    J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
    Cortese BD; Dusetzina SB; Luckenbaugh AN; Al Hussein Al Awamlh B; Stimson CJ; Barocas DA; Penson DF; Chang SS; Talwar R
    J Clin Oncol; 2023 Oct; 41(29):4664-4668. PubMed ID: 37290029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.